Merck may trail the first movers in the coming onslaught of blockbuster biosimilars, but the pharma giant is heralding a crop of late-stage copycat treatments it believes can snag a share of the soon-to-boom market.

…read more

Source: Merck touts a bright future in biosimilars with a stable of would-be blockbusters


0 No comments